Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranolazine extended-release - Gilead Sciences

Drug Profile

Ranolazine extended-release - Gilead Sciences

Alternative Names: CVT 303; CVT 3041; KEG 1295; RAN D; Ran4; Ranexa; Ranolazine hydrochloride; RS 43285; RS 43285-003; RS 43285-193

Latest Information Update: 20 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntex Pharmaceuticals International
  • Developer CV Therapeutics; Gilead Sciences; Kissei Pharmaceutical; Menarini; North Shore-Long Island Jewish Health System; Ohio State University; University of Rochester
  • Class Acetanilides; Anti-ischaemics; Antihyperglycaemics; Ischaemic heart disorder therapies; Piperazines; Small molecules
  • Mechanism of Action Partial fatty acid oxidation inhibitors; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angina pectoris
  • Phase III Acute coronary syndromes; Atrial fibrillation; Type 2 diabetes mellitus
  • Phase II Amyotrophic lateral sclerosis; Aortic valve stenosis; Diastolic heart failure; Left ventricular hypertrophy; Long QT syndrome; Myocardial ischaemia; Myotonic dystrophy
  • Discontinued Intermittent claudication; Ventricular arrhythmias

Most Recent Events

  • 31 Dec 2018 Gilead Sciences completes a phase II trial in Long QT syndrome type 3 in USA (PO) (NCT01648205)
  • 24 Jun 2018 Biomarkers information updated
  • 11 Jun 2018 Phase-II clinical trials in Amyotrophic lateral sclerosis in USA (PO) (NCT03472950)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top